after joining the study, you will complete a consent form and provide basic personal information such as age and sex.

the study team will record your medical history, including the diagnosis of c3 glomerulopathy or primary ic‑mpgn and any previous treatments.

baseline laboratory tests will be performed to measure protein in the urine (upcr), kidney function (egfr), and other relevant biomarkers.

the first dose of pegcetacoplan (aspaveli 1080 mg solution for infusion) will be administered by subcutaneous injection.

each injection contains a dose of 308.6 mg of the active substance.

the exact schedule for subsequent injections will follow the study protocol, which is defined by the investigators.

you will return for visits at 1 month, 3 months, 6 months, and 12 months after the first injection, and thereafter every 6 months for the duration of the study.

at each visit, clinical evaluation and laboratory tests will be repeated to monitor upcr, egfr, and other biomarkers.

questionnaires about fatigue and work productivity may be completed, if applicable.

the primary effectiveness goal is to achieve an upcr of less than 1 g/g at 6 months after starting pegcetacoplan.

secondary goals include reductions of proteinuria by at least 50 %, reaching lower upcr thresholds, and improvements in kidney function measured by egfr.

throughout the study, you will be monitored for serious adverse events, infections, malignancies, and acute kidney injury.

any new symptoms or laboratory abnormalities will be recorded and evaluated by the study physicians.

if the investigator determines a change in the medication dose is needed, the new dose and the reason for the change will be documented.

if you switch from pegcetacoplan to another complement inhibitor such as iptacopan, or if the medication is stopped and later restarted, additional assessments will be performed at 2 weeks, 1 month, 3 months, 6 months, and 12 months after the change.

at the end of the study period (estimated June 2032), a final visit will be conducted.

the last set of laboratory measurements, questionnaires, and a summary of your treatment course will be recorded.

all collected information will be used to evaluate the real‑world effectiveness and safety of pegcetacoplan in patients with c3 glomerulopathy or primary ic‑mpgn.